Research Article
No Early Effect of Intrathecal Rituximab in Progressive Multiple Sclerosis (EFFRITE Clinical Trial)
Figure 1
Study timeline and main results. (a) Schedule of investigations (from day 0 to 360). (b) Lymphocyte count decreased in treated groups. OPN and NFL levels remained mostly stable over time. . (c) Leptomeningeal enhancing lesion (LME) on basal MRI (#6), late-acquired axial FLAIR-enhanced sequence. Absence of overt change in control MRIs (not shown).
(a) |
(b) |
(c) |